As expected, the first series of new molecular CPT® codes went into effect on January 1, 2012. To support our clients as they navigate this new coding landscape, we have posted in the Knowledge Center initial reviews of the evidence for the diseases and tests associated with all of the 193 newly implemented codes.

• Cancer
• Other
• Pharmacogenetic
• Single Gene
• Tissue Typing

The new CPT codes for molecular diagnostic testing will provide payers and providers with clarity with regard to the type of testing being requested and/or performed. Hayes’ GTE evidence reviews supply you with the information you need to make informed decisions about managing and paying for these molecular tests.

To view a listing of other topics covered in the Genetic Test Evaluation program, please click into the category below:

• Cancer
• Other
• Pharmacogenetic
• Single Gene

If you are not a Hayes client, you can purchase any of our evidence reviews as a single report. Contact us for more information.